Mumps

Global Vaccine Market Analysis Report 2022-2027: Size, Forecasts, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 26, 2022
Health, Pharmaceutical, CSL Limited, Mumps, Infection, Pediatrics, Ebola, Measles, Prevalence, DPT, Janssen Pharmaceuticals, Chickenpox, Tetanus, COVID-19, Vaccination, Research, Immunization, Man, Diphtheria, Travel, HPV, Health, Death, DPT vaccine, Vaccine, Coronavirus, US, World Bank, Diagnosis, Cervical cancer, Awareness, Haemophilus influenzae, WHO, MMR, BCG, DTP, Meningitis, Ageing, Merck & Co., Inactivated vaccine, Patient, Bill & Melinda Gates Foundation, Industry, Insight, Sanofi Pasteur, Invention, GlaxoSmithKline, Hepatitis, Genetically modified bacteria, Pfizer, UNICEF, Pharmaceutical industry, Growth, Adult, Pneumonia, Haemophilus, Shingles, Rotavirus, Rubella

The "Global Vaccine Market, Size, Global Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Vaccine Market, Size, Global Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Vaccines Market is anticipated to reach US$ 86.2 Billion by the year 2027 from $52.5 Billion in 2021.
  • The increasing consumer awareness of adequate immunization for killing various infections catalyzes vaccine market development.
  • Segmentation of Global Vaccines Market:
    In terms of end-user, the vaccine market is divided into pediatrics and adults.

Huma calls for safeguarding of scientific collaboration to tackle global health challenges during event at World Economic Forum

Retrieved on: 
Wednesday, May 18, 2022
Diabetes, Global Innovation through Science and Technology initiative, Hospital, Knowledge, University, COVID-19, Degenerative disease, Alzheimer's disease, Atrial fibrillation, Coronavirus, Environment, Multilateralism, Patient, Vaccine, Solution, Health, Therapy, World Economic Forum, Clinical trial, Dr. Jeyasekharan Hospital & Nursing Home, Mumps, Mortality, Thought, Technology, Research, Global health, Software, Home, Partnership, Vahdat, Gaps, NHSX, Head, Infection, LinkedIn, Movement, Founder, Huma, Cancer, Medical device, AstraZeneca, Pharmaceutical industry

COVID-19 showed that rapid scientific advances can be achieved through global collaboration across disciplines, geographies and sectors.

Key Points: 
  • COVID-19 showed that rapid scientific advances can be achieved through global collaboration across disciplines, geographies and sectors.
  • "COVID-19 exposed the glaring inequalities in global health, the gaps in our knowledge and the faults in our systems.
  • "The World Economic Forum provides leading start-ups like Huma a platform to help tackle important problems such as providing more resilient, efficient, and equitable healthcare systems," said Verena Kuhn, Head, Global Innovators Community at the World Economic Forum.
  • "Scientific collaboration is vital in finding such healthcare solutions and Huma can provide important insights into how digital can be better leveraged in public-private health care collaboration."

Huma calls for safeguarding of scientific collaboration to tackle global health challenges during event at World Economic Forum

Retrieved on: 
Wednesday, May 18, 2022
Diabetes, Global Innovation through Science and Technology initiative, Hospital, Knowledge, University, COVID-19, Degenerative disease, Alzheimer's disease, Atrial fibrillation, Coronavirus, Environment, Multilateralism, Patient, Vaccine, Solution, Health, Therapy, World Economic Forum, Clinical trial, Dr. Jeyasekharan Hospital & Nursing Home, Mumps, Mortality, Thought, Technology, Research, Global health, Software, Home, Partnership, Vahdat, Gaps, NHSX, Head, Infection, LinkedIn, Movement, Founder, Huma, Cancer, Medical device, AstraZeneca, Pharmaceutical industry

COVID-19 showed that rapid scientific advances can be achieved through global collaboration across disciplines, geographies and sectors.

Key Points: 
  • COVID-19 showed that rapid scientific advances can be achieved through global collaboration across disciplines, geographies and sectors.
  • "COVID-19 exposed the glaring inequalities in global health, the gaps in our knowledge and the faults in our systems.
  • "The World Economic Forum provides leading start-ups like Huma a platform to help tackle important problems such as providing more resilient, efficient, and equitable healthcare systems," said Verena Kuhn, Head, Global Innovators Community at the World Economic Forum.
  • "Scientific collaboration is vital in finding such healthcare solutions and Huma can provide important insights into how digital can be better leveraged in public-private health care collaboration."

SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act

Retrieved on: 
Friday, May 6, 2022
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Mumps, COVID-19, Forward-looking statement, Hepatitis, Chickenpox, NASDAQ, PCAOB, Sinovac Biotech, Company, EV71, Annual report, Holding, WHO, Program, Holding Foreign Companies Accountable Act, Private Securities Litigation Reform Act, Form 20-F, Chinese government award for outstanding self finance students abroad, Vaccine, Hepatitis A, Influenza A virus subtype H1N1, Polio, U.S. Securities and Exchange Commission, SEC, Infection, Terminology, H5N1, EUL, Research

Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, is aware that the Company has been identified by the United States Securities and Exchange Commission (SEC) under the Holding Foreign Companies Accountable Act of the United States (the HFCAA) on May 4, 2022.

Key Points: 
  • Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, is aware that the Company has been identified by the United States Securities and Exchange Commission (SEC) under the Holding Foreign Companies Accountable Act of the United States (the HFCAA) on May 4, 2022.
  • Similar to other companies that have also been identified, SINOVAC notes such identification resulted from the Companys filing of its annual report on Form 20-F for the fiscal year ended December 31, 2021.
  • SINOVAC will continue to closely monitor developments and explore options in relation to the HFCAA.
  • Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases.

Physicians for Informed Consent Updates Its Information Statement About Vaccines and Immunocompromised Schoolchildren, Includes Data on COVID-19 Vaccines

Retrieved on: 
Monday, March 28, 2022
Risk, Virus, Family, MMR, Vaccination, Chickenpox, HPV, Measles, Public health, Parent, Friends, Poliovirus, Bacteria, Vaccine, TIV, Rubella, Environment, Immunodeficiency, PIC, Statistics, Influenza, Tetanus, Whooping cough, School, IPV, Diphtheria, LAIV, Safety, Mumps, Haemophilus influenzae, DPT vaccine, COVID-19, GLOBE, Hepatitis B, Science, Child, COVID-19 vaccine, Informed consent, Infection, Pharmaceutical industry, Physician

NEWPORT BEACH, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Physicians for Informed Consent ( PIC ), an educational nonprofit organization focused on science and statistics, has released an update to its information statement entitled "Vaccines: What About Immunocompromised Schoolchildren?"

Key Points: 
  • NEWPORT BEACH, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Physicians for Informed Consent ( PIC ), an educational nonprofit organization focused on science and statistics, has released an update to its information statement entitled "Vaccines: What About Immunocompromised Schoolchildren?"
  • Thus, informed consent and informed refusal in vaccination are both logical and moral, and there is no justification to mandate schoolchildren receive COVID-19 vaccines, or any other vaccines."
  • PIC delivers data on infectious diseases and vaccines, and unites doctors, scientists, healthcare professionals, attorneys, and families who support voluntary vaccination.
  • In addition, the PIC Coalition for Informed Consent consists of over 300 U.S. and international organizations.

Physicians for Informed Consent Opposes COVID-19 Vaccine Mandate for School Attendance and Doctor Censorship Bills in California

Retrieved on: 
Tuesday, March 15, 2022
Decision-making, K-12, Mumps, Informed consent, First, Vaccine, School, Hepatitis B, Statistics, Rubella, Public health, Risk, COVID-19, Science, Senate, Tetanus, Measles, Assembly, Immunodeficiency, Child, Physician, SB, Whooping cough, Chickenpox, Diphtheria, PIC, District of Columbia Voting Rights Amendment, COVID-19 vaccine, Haemophilus influenzae, Pharmaceutical industry, Haemophilus

NEWPORT BEACH, Calif., March 15, 2022 /PRNewswire-PRWeb/ -- Physicians for Informed Consent ( PIC ), an educational nonprofit organization focused on science and statistics, has submitted opposition letters to California Senate Bill 871 (SB 871) and Assembly Bill 2098 (AB 2098).

Key Points: 
  • NEWPORT BEACH, Calif., March 15, 2022 /PRNewswire-PRWeb/ -- Physicians for Informed Consent ( PIC ), an educational nonprofit organization focused on science and statistics, has submitted opposition letters to California Senate Bill 871 (SB 871) and Assembly Bill 2098 (AB 2098).
  • SB 871 proposes a COVID-19 vaccine mandate (without any religious or personal belief exemption) for daycare and K-12 public and private school attendance in California.
  • SB 714 effectively censored physicians in California from expressing their professional medical opinion, through the act of writing letters to schools, that a child's risk of one or more mandated vaccines for school attendance is more than the benefit.
  • Read the Physicians for Informed Consent letters and discuss them with your legislators:

GreenLight Biosciences Holdings, PBC (GRNA) enters into multitarget licensing agreement with Serum Institute of India to develop and commercialize messenger RNA products for emerging markets globally

Retrieved on: 
Monday, March 14, 2022
Mumps, Measles, Family, Private Securities Litigation Reform Act, RNA transfection, Green-light, Partnership, Therapy, Agriculture, Haemophilus influenzae, BCG, Developing country, Health, GRNA, Shingles, Forward-looking statement, Technology transfer, GLOBE, Vaccine-preventable diseases, Population, COVID-19, SII, Global health, Tetanus, RNA, Serum Institute of India, Vaccine, CEO, Pharmaceutical industry, Nasdaq, Diphtheria

Serum Institute of India has engaged GreenLight to design three messenger RNA products, including a vaccine for shingles.

Key Points: 
  • Serum Institute of India has engaged GreenLight to design three messenger RNA products, including a vaccine for shingles.
  • GreenLight will make a technology transfer of its scalable and cost-effective manufacturing process to Serum Institute of India.
  • Serum Institute of India will pay all development, manufacturing, and commercialization costs for each product in the emerging markets.
  • BOSTON and PUNE, India, March 14, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings PBC today announced a licensing agreement with Serum Institute of India, Pvt, Ltd., aimed at accelerating accessibility to messenger RNA products in emerging markets globally.

Antimicrobial Coatings Market to Cross $7.5 Billion by 2027 - Discover the Key Driving Factors, Challenges, and Degree of Competition - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 23, 2022
Chemicals, Plastics, Manufacturing, Mumps, Awareness, Germination, Measles, Sick building syndrome, COVID-19, Chickenpox, Infection, CAGR, Research, Rubella, Renewable energy, Vaccine, Growth

The "Antimicrobial Coatings Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antimicrobial Coatings Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global antimicrobial coatings market reached a value of US$ 4.16 billion in 2021.
  • Looking forward, the market is projected to reach US$ 7.52 billion by 2027, exhibiting a CAGR of 10.2% during 2022-2027.
  • This report provides an analysis of the key trends in each sub-segment of the global antimicrobial coatings market, along with forecasts at the global and regional from 2022-2027.

Sinovac Amends Shareholder Rights Plan

Retrieved on: 
Tuesday, February 22, 2022
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Mumps, Hepatitis A, Sinovac Biotech, WHO, NASDAQ, Chinese government award for outstanding self finance students abroad, EV71, Chickenpox, COVID-19, Company, Vaccine, Campus Biotech, Terminology, Infection, H5N1, Forward-looking statement, Influenza A virus subtype H1N1, Private Securities Litigation Reform Act, Research

Sinovac Biotech Ltd. (Sinovac or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan.

Key Points: 
  • Sinovac Biotech Ltd. (Sinovac or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan.
  • The amendment extends the expiration date of the plan from February 22, 2022 to February 22, 2023.
  • The EV71 vaccine, an innovative vaccine developed by SINOVAC against hand foot and mouth disease caused by EV71, was commercialized in China in 2016.
  • Additionally, the triggering of a shareholder rights plan is nearly unprecedented, and the Company cannot predict the impact on the Company or its stock price as a result of the trigger of the rights plan.

Global Adult Vaccine Industry Trends and Opportunities, 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 18, 2022
Biotechnology, Pharmaceutical, Health, Measles, GlaxoSmithKline, DPT vaccine, Bacterial pneumonia, Respiratory system, Hepatitis, Man, Cervical cancer, CDC, Government, Prevalence, Influenza, CSL Limited, Fungus, Rubella, Vaccine, Merck & Co., Death, Baloxavir marboxil, HPV, Adult, Degenerative disease, Shingles, Virus, Billion, Center, Respiratory tract, Chickenpox, Pfizer, MMR, Sanofi Pasteur, USD, Rubella vaccine, Centers for Disease Control and Prevention, Thoracic aortic aneurysm, Research, Mumps, BLA, COVID-19, Travel, Vaccination, TAA, CAGR, Pharmaceutical industry, Growth, Neisseria meningitidis, Pneumonia

The "Global Adult Vaccine Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Adult Vaccine Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Recently, the increasing prevalence of diseases and novel vaccine technologies has been significant drivers for the global adult vaccines market.
  • In addition, increased research in vaccine technologies and increasing government support also support the growth of the global adult vaccines market.
  • According to this report Global Adult Vaccine Industry is projected to grow with a CAGR of 6% from 2021-2027.